A Pharmaceutical Company's View on Supply-Chain Security: A Perspective from Pfizer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Pharmaceutical Company's View on Supply-Chain Security: A Perspective from Pfizer
The author offers perspectives on ways in which pharmaceutical companies and other stakeholders in the supply chain can confront the threat of counterfeit products, cargo theft, illegal diversion, and economically motivated adulteration.


Pharmaceutical Technology
Volume 35, Issue 9

A dangerous melamine substitution in nutritional products in China, the $75-million heist of drugs from Eli Lilly's Connecticut warehouse, and 149 deaths in the US from contaminated heparin are all examples of headline-making news stories of pharmaceutical supply-chain attacks. These types of threats are occurring with greater frequency, and concern for patient safety is escalating. Counterfeit products, cargo theft, illegal diversion, and economically motivated adulteration are creating greater challenges for Pfizer and other global pharmaceutical companies while putting patient safety at risk.

The World Health Organization (WHO) estimates that 10% of all pharmaceuticals in the global supply chain are counterfeit, and that level may reach 70% in some developing countries (1). Although it is impossible to accurately quantify the extent of the global problem, the impact of counterfeiting has been estimated to be as high as $200 billion per year (2). Other supplychain security problems also are on the rise. From 2007 to 2009, for example, the rate of pharmaceutical cargo theft in the US jumped 350% (3).

Contributing factors

Several business trends are contributing to the problem. Cost and pricing pressures, generic-drug competition, and challenges with R&D productivity, coupled with the loss of exclusivity of key products—all are pushing pharmaceutical companies toward more complex supply chains, increased levels of contract manufacturing, and more licensing agreements. These issues, along with companies' efforts to expand into new and emerging markets, are providing ample opportunity for criminals to illegally enter the supply chain.

Partnerships

We all realize that we operate in a global marketplace. The pharmaceutical industry's raw materials may originate in one part of the world while products are manufactured in another. Packaging can occur in many markets, and products are transported and sold globally. Supply-chain security is an international issue and a global health imperative.

To successfully address the problem, pharmaceutical companies, regulators, suppliers, law enforcement, and other supply-chain partners must work closely and cooperatively together. Collaboration already is occurring through organizations such as Rx–360, World Health Organization, the Pharmaceutical Security Institute, the Partnership for Safe Medicines, and Interpol to name a few.

The pharmaceutical industry, consumers, and the public at large should realize that we are all in this together. Effective global solutions are required to shore up the entire supply-chain security system because criminals will always attack the weakest links to steal, divert, counterfeit, or adulterate drug products.

The main players in the supply chain—pharmaceutical companies and their external partners, trade groups, law enforcement, government agencies, and industry consortiums—can influence change. Whether by working together or in part (i.e., as a group proposing a strategy, by influencing another partner in the chain, by supporting an initiative, or by implementing a specific requirement), we can, for example, increase global penalties for supply-chain crimes, increase public awareness of supply-chain risks, share best practices, and work to develop harmonized global supply-chain solutions. We must embrace opportunities for the industry and its stakeholders to work together to keep the pharmaceutical supply chain safe for millions of patients who depend upon the products it provides to improve their lives. They expect safe and effective medicines, and it is the industry's responsibility to deliver them.

Holistic approach to supply-chain security

External partnerships and cooperation are vital to keep the global supply of medicines safe, but pharmaceutical companies also can do a great deal to maximize supply-chain security at the organizational level within their companies. The industry can start by taking a holistic approach to supply-chain security from the procurement of raw materials through product delivery. Risk-management principles and integrated layers of protection are important at each juncture of the supply-chain continuum. Pharmaceutical companies need to understand and integrate the myriad internal organizations and activities that touch their supply chains and collaborate to reach effective solutions.

The areas that make up the supply chain—including raw-materials procurement, manufacturing (internal manufacturing and through external suppliers), transportation, warehousing, quality, distribution, and marketplace monitoring—must be aligned and work together for maximum effectiveness.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
9%
All of the above.
45%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here